Literature DB >> 22047578

Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

Steven Van Laecke, Raymond Vanholder.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22047578     DOI: 10.1056/NEJMc1110239

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  The extinguished BEACON of bardoxolone: not a Monday morning quarterback story.

Authors:  John A Tayek; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2013-02-28       Impact factor: 3.754

Review 2.  Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy.

Authors:  Bing Li; Shujun Liu; Lining Miao; Lu Cai
Journal:  Exp Diabetes Res       Date:  2012-05-08

3.  Keap1 hypomorphism protects against ischemic and obstructive kidney disease.

Authors:  Roderick J Tan; Dionysios V Chartoumpekis; Brittney M Rush; Dong Zhou; Haiyan Fu; Thomas W Kensler; Youhua Liu
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.379

Review 4.  Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives.

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Madalina Ioana Anton; Mariana Floria; Petronela Nicoleta Seritean Isac; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Claudia Florida Costea; Manuela Ciocoiu; Ciprian Rezus
Journal:  Biomolecules       Date:  2022-09-02

5.  Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents.

Authors:  Macaulay Onuigbo
Journal:  Nephron Extra       Date:  2013-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.